Netscientific Share Discussion Threads

[blakieboy7] 20/10/2022 16:15

PDSB up 15% so far today, this should move further

[blakieboy7] 12/10/2022 16:54

Nice close

[kingston78] 12/10/2022 09:02

The share price is still under the last placing price of 67 p.

From my experience in the corporate M&A sector I would not be surprised if one or more of NSCI's investee companies are bought out or floated onto the London Stock Exchange for tens of millions of pounds. That will be an earth-shattering event that make professional investors look silly because they have not invested in NSCI.

I look forward to the day when the share price reaches its old peak of more than 180p in June 2021.

[senttothegallows] 12/10/2022 08:33

£1 is the least this should be IMHO

[blakieboy7] 12/10/2022 08:30

Nice start

[senttothegallows] 12/10/2022 06:42

We are valued at about a third of NAV we have alot of catching up to do at some point. If not we get bought out imho

[blakieboy7] 12/10/2022 06:30

Some catching up to do! Hopefully we'll gain more momentum today

[blakieboy7] 11/10/2022 22:02

Pdsb up 17% so we've done catching up to do!!

[kingston78] 10/10/2022 14:07

Evgen Pharma has gone up by 120% today. It caught my eye early on. However, no one has a bottomless pocket so I did not buy into the action when it rose by 35%.

Anyway, I am waiting for the day when NSCI will more than double in a day and then double again in short order.

It is difficult for me to understand that how NSCI can be so undervalued. The directors and the company's advisors should promote the company more actively.

[blakieboy7] 06/10/2022 09:31

That's a bit better

[kingston78] 06/10/2022 09:28

I agree with Simon Thompson's assessment of the company. I would like to say that when investors wake up to the attraction of the company they will pay a premium over the fair value.

In my experience of other companies, if one of its investments hits the jackpot the current share price will have looked silly (cheap, really cheap). There have been situations where the child is bigger than the parent (Vodafone is the first that comes to mind - part of the formerly listed Racal Electronics which also demerged Chubbs and some others to realise value for investors).

[sev22] 05/10/2022 18:09

'Unloved, and materially undervalued'

An investment company is trading on a massive discount to the underlying value of its investments.

October 5, 2022
By Simon Thompson

*Half-year pre-tax loss increases 12 per cent to £1.7mn.
*Fair valuation of portfolio investments down slightly to £29.2mn (125p a share).
*Capital under advisory up 11 per cent to £24.6mn.

Investors are taking an overly cautious stance on NetScientific (NSCI:50p), an investment company that backs early-stage life sciences, healthcare and technology businesses. The shares not only trade at a massive discount to the 125p a share fair valuation of the portfolio, but that valuation ascribes no value to EMV Capital, the company’s investment finance boutique.

EMV increased capital under advisory by 11 per cent to £24.6mn, a point worth noting given that EMV has a carried interest arrangement with investors it has introduced into its portfolio companies and is entitled to a share of profits on realisation of their investments. The carried interests’ range between 10 per cent and 20 per cent of profits above a minimum return hurdle rate of up to 10 per cent.

One of the portfolio companies is Q-bot, a London-based robotics and artificial intelligence company that has developed a patented energy saving robotic system for applying insulation in tight spaces and suspended floors (to reduce heat loss and prevent draughts, damp and mould). Following a £1.62mn funding round, the fair valuation of the company’s 23.7 per cent stake more than doubled to £2.1mn (at 30 June 2022) and Netscientific has since realised £0.25mn of cash proceeds and booked a £0.11mn profit by selling down part of its holding. Netscientific also has exposure to carried interests on a 15.6 per cent indirect stake in Q-bot through funds managed by EMV.

It’s not the only company that is attracting attention from outside investors as chief executive Ilian Iliev notes that "within several of our companies, we are working on substantial liquidity events or routes to exit". The point being that further realisations will boost the company’s net cash position of £1.9mn and provide reassurance to investors that the valuations are well supported.

The company’s portfolio also includes a $4.4mn (£3.9mn) stake in Nasdaq-listed PDS Biotechnology Corporation (US:PDSB), a company that is developing cancer immunotherapies and infectious disease vaccines based on its proprietary Versamune® T‑cell activating technology platform. PDS has ongoing Phase II clinical trials with world leading organisations, Merck, National Cancer Institute, MD Anderson and Mayo Clinic.

PDS has just completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for its lead candidate, PDS0101, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced human papilloma virus head and neck squamous cell carcinoma. PDS signed a $35m venture debt financing agreement in August, so is well funded although its shares are unloved, too. The rout on Nasdaq reduced the carrying value of the investment and largely explains the decline in Netscientific's portfolio valuation.

In addition, Netscientific holds a 62.5 per cent interest (fair valuation of £11mn) in Glycotest, a US‑based diagnostics company that is commercialising tests for patients with life‑threatening liver diseases, targeted at early‑stage diagnosis to reduce mortality for this growing patient population. Glycotest accounted for £0.65mn of the reported half-year pre-tax loss of £1.7mn, but there was no cash impact for Netscientific as Fosun Pharmaceutical is funding the working capital requirements of the investee company, and will continue to do so.

The bottom line is that if you only value EMV at £3.5mn, a low-ball valuation in my view, then the combined value of EMV, the holding in PDS, balance sheet cash and the directly held stake in Q-bot back up all the company’s market capitalisation of £11.6mn. This leaves over £18mn of directly held investments in the price for free as well as valuable carried interests on £24.6mn of capital under advisory. BUY.

[sev22] 05/10/2022 10:22

Netscientific Portfolio Company Vortex CEO says pharma and biotech to drive next stage of growth:

[kingston78] 03/10/2022 20:15

I noticed that the share chart was reversing the downward trend this morning, rising a little before the positive announcement which has propelled the share much higher. Anyway, the share price is still below the last placing price. It is illogical for it to remain so low.

I wouldn't be surprised that there will be an announcement that the company will have sold a chunk of its investments privately at substantial profit or propose an IPO for one of its investments.

[sev22] 03/10/2022 18:55

NetScientific portfolio company PDS ahead of schedule for key cancer therapy trial:

[sev22] 03/10/2022 15:31

Broker WH Ireland has a fair value of 200.00p per share.

[blakieboy7] 03/10/2022 14:36

I particularly like this - The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule. This, along with the recent capital raise, allows us to efficiently advance our clinical programs.

[zen12] 03/10/2022 14:34

Well it's in the bag now! We all know how difficult FDA can be getting through level 2 is a massive achievement..!

[blakieboy7] 03/10/2022 14:31

TIDMNSCINetScientific PLC03 October 2022NetScientific plc("NetScientific", the "Group" or the "Company")PDS completes End-of-Phase 2 meeting with FDANetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA(R) (pembrolizumab) for the treatment of unresectable, recurrent/metastatic human papilloma virus (HPV) 16-positive head and neck squamous cell carcinoma (HNSCC).Earlier this year, the FDA granted Fast Track designation to the combination of PDS0101 and KEYTRUDA(R) (pembrolizumab) for the treatment of HPV16-positive HNSCC. The FDA's Fast Track designation program is designed to aid in the development and to expedite the review of drug candidate applications that could potentially treat serious or life-threatening conditions. Treatments granted this designation are given the opportunity to have more frequent meetings and interactions with the FDA throughout the entire drug development and review process, with the goal of moving promising new drugs more rapidly through the process.Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech commented: "We are very pleased with the guidance received from FDA on key elements of the clinical program that will support the submission of a Biologics License Application (BLA) for our lead asset PDS0101. The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule. This, along with the recent capital raise, allows us to efficiently advance our clinical programs."PDS0101 represents a potentially transformative treatment approach for HPV16-positive HNSCC patients. We are committed to providing physicians and patients a possibly more effective and safer treatment option to address this debilitating and deadly disease."Dr. Ilian Iliev, CEO of NetScientific, commented: "We are pleased with PDS' continued and systematic progress on its business objectives, despite unfavourable capital markets conditions. Building on momentum from the FDA Fast Track designation in June 2022, and the subsequent $35m venture debt facility in August 2022, PDS is now well positioned for further progress in its PDS101 clinical programme."

[blakieboy7] 03/10/2022 14:31

It's about bloody time!!

[zen12] 03/10/2022 14:10

RNS out!"PDS0101 represents a potentially transformative treatment approach for HPV16-positive HNSCC patients. We are committed to providing physicians and patients a possibly more effective and safer treatment option to address this debilitating and deadly disease."

[kingston78] 30/9/2022 14:09

The CEO has commented, " We have a well-balanced portfolio across sectors and geographies, with businesses at different stages of their development, and adaptable for a changing sectoral and macro-economic dynamics. Within several of our companies, we are working on substantial liquidity events or routes to exit."

I look forward to the days when the company sells some of its investments at substantial profit.